AOPEP and congenital bilateral aplasia of vas deferens from CFTR mutation: IONIS-APO(a)Rx, an oligonucleotide targeting lp(a), could reduce lp(a) levels by 66–92%, OxPL-ApoB and OxPL-apo(a) decreased moderately, which play a vital role in pathogenesis of CAVD (71).